March S&P 500 E-Mini futures (ESH25) are up +0.05%, and March Nasdaq 100 E-Mini futures (NQH25) are down -0.08% this morning as investors awaited a new round of U.S. economic data, remarks from ...

Health-care companies rose after strong earnings from one obesity-drug maker. Eli Lilly shares rose after it reiterated its forecast for 32% 2025 revenue growth, amid rising demand for its Zepbound ...

Shares of Bristol Myers Squibb Co. BMY shed 3.84% to $57.42 Thursday, on what proved to be an all-around mixed trading ...

Recent health news includes Bristol Myers' projected revenue dip due to generic competition and cost cuts, Trump's tariffs ...

The move comes less than a year after the company attempted to save $1.5 billion through the layoff of some 2,200 employees.

Financial discipline remained a priority, with approximately $1.1 billion of the targeted $1.5 billion in savings already realized. The company has identified an additional $2 billion in savings, with ...

We recently published a list of Jim Cramer Tells Viewers To Not Trust Billionaires & Discusses These 11 Stocks.

By Michael Erman and Sriparna Roy (Reuters) -Bristol Myers Squibb on Thursday said its 2025 revenue would fall more sharply ...

Bristol Myers Squibb clocked $10 million in sales for new schizophrenia drug Cobenfy in the fourth quarter of 2024, with the ...

Bristol Myers Squibb reported strong fourth-quarter earnings but its outlook for 2025 failed to meet expectations.

Bristol Myers Squibb will make even deeper cuts to its organization to enhance efficiencies as it faces the 2028 loss of ...

Shares in Bristol-Myers Squibb traded lower after the drug maker gave 2025 guidance that undershot expectations. Bristol expects sales of about $45.5 billion in 2025, compared with the $46.3 billion ...